| 摘要 |
<p>The invention relates to substituted tetrahydronaphthalenes of formula (I), the physiologically tolerated salts thereof, the use thereof, medicaments containing at least one substituted tetrahydronaphthalene according to the invention and the use of the substituted tetrahydronaphthalenes according to the invention and derivatives thereof as MCH antagonists, wherein in the case that X = O, C(R43)(R43'), B = (C<sub>1</sub>-C<sub>6</sub>)alkyI, (C<sub>1</sub>-C<sub>4</sub>)alkoxy-(C<sub>1</sub>-C<sub>4</sub >)alkyl, hydroxy-(C<sub>1</sub>-C<sub>6</sub>)alkyl, a 3- to 10-membered mono-, bi- or spirocyclic non-aromatic ring, which can contain 0 to 3 heteroatoms, selected from the group oxygen, nitrogen and sulfur, wherein the ring system can be additionally substituted with one or several of the following substituents: F, CF<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)alkyI, O-(C<sub>1</sub>-C<sub>8</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy-(C<sub>1</sub>-C<sub>4</sub >)alkyI, hydroxy-(C<sub>1</sub>-C<sub>4</sub>)alkyl, oxo, CO(R64), hydroxy; wherein in the case that X = C(R43)(R43'), L3 = C(R62)(R63)O, and a 4- to 10-membered mono-, bi- or spirocyclic non-aromatic ring, which contains 1 to 3 heteroatoms, selected from the group oxygen, nitrogen and sulfur, wherein the ring system can be additionally substituted with one or several of the following substituents: F, CF<sub>3</sub>, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>1</sub>-C<sub>4</sub>)alkoxy-(C<sub>1</sub>-C<sub>4</sub >)alkyl, hydroxy-(C<sub>1</sub>-C<sub>4</sub>)alkyl, oxo, CO(R64), hydroxy.</p> |
